Prostate Cancer Prevention and Treatment Technologies: Comprehensive Global Market Analysis - ResearchAndMarkets.com
2024-02-12
放射疗法
DUBLIN--(BUSINESS WIRE)--The "Prevention and Treatment of Prostate Cancer: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
'Prevention and Treatment of Prostate Cancer: Technologies and Global Markets'
The global market for prostate cancer care reached $35.3 billion in 2022. This market is expected to reach $56.4 billion by the end of 2028, growing at a CAGR of 8.3% from 2023 through 2028.
As the second most diagnosed male cancer in the world, prostate cancer affects roughly 1.4 million people and kills more than 370,000 men each year, which represents about 4% of all cancer deaths worldwide. This cancer ranges from being a non-aggressive, slow-growing type that can do without treatment to an aggressive, fast-growing disease that needs intervention and timely treatment. Hence, early detection/screening, diagnosis and staging of prostate cancer are critical.
The global market for prostate cancer screening and detection is projected to grow at a CAGR of 5.8% to reach $19.8 billion by the end of 2028. It is estimated that over 60% of age-eligible men remain unscreened for prostate cancer. A large, underserved population of unscreened and inadequately screened patients represents a significant opportunity for non-invasive biomarker tests in the prostate cancer screening market.
The global market for prostate cancer pharmaceuticals was valued at $16.0 billion in 2022 and is expected to reach $29.6 billion by the end of 2028, at a CAGR of 11.0% during the forecast period. Continued incidence of prostate cancer, the world's growing elderly population, and increasing therapeutic innovations are key driving factors in the market for prostate cancer drugs.
The direct cost for radical prostatectomy was estimated at $3.6 billion in 2022. This cost is expected to rise to $4.8 billion by the end of 2028. The growing popularity of robot-assisted laparoscopic prostatectomy (RALP) is expected to impact the overall radical prostatectomy market. Improved screening programs will result in an increase in radical prostatectomies, as this procedure is preferred in early detection stages.
The radiotherapy device market is expected to grow as the incidence of prostate cancer worldwide continues to increase and better and more accurate imaging technologies combined with precise treatment strategies are developed. This market is expected to reach $2.2 billion by the end of 2028.
This research study analyzes the state of prostate cancer care, including screening, detection and treatment, offers revenue forecasts, assesses future trends, and provides recommendations for the success of market participants. The scope of the study is global. This report estimates market data for 2022 (the base year) and provides forecasts for 2023 through 2028. Figures for 2023 are estimated, except where actual results have been reported. This report includes forecasts by product type and region from 2023 through 2028. Genetic testing for inherited prostate cancer risk assessment is beyond the scope of the report.
The Report Includes
31 data tables and 63 additional tables
An overview of the global market for the technologies for prevention and treatment of prostate cancer
Analysis of global market trends, featuring historical revenue data for 2020-2022, estimated figures for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028
Evaluation of the current market size and revenue growth prospects specific to prevention and treatment of prostate cancer, accompanied by a market share analysis by test type, treatment type, drug type and geographic region
Description of several types of prostate cancer, namely acinar adenocarcinoma, ductal adenocarcinoma, transitional cell (or urothelial) cancer, small cell prostate cancer and carcinoid and sarcomas
Description of biomarker tests such as the prostate-specific antigen (PSA) test, digital rectal exam (DRE) and prostate biopsy, and a discussion on their advantages and limitations
Information on poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, their limitations and approvals related to their use as targeted therapy for prostate cancer
Coverage of approvals for metastatic castration resistant prostate cancer (mCRPC), and collaborations and licensing agreements for the treatment of prostate cancer
Evaluation of the current and future market potential and an analysis of the regulatory framework and reimbursement scenarios
Review of patents, product pipelines, ESG trends and emerging technologies related to prevention and treatment of prostate cancer
Market share analysis of the key companies in the industry and coverage of mergers & acquisitions, joint ventures, collaborations, partnerships and other market strategies
Profiles of leading market participants
Key Attributes:
Report Attribute
Details
No. of Pages
157
Forecast Period
2023 - 2028
Estimated Market Value (USD) in 2023
$37.9 Billion
Forecasted Market Value (USD) by 2028
$56.4 Billion
Compound Annual Growth Rate
8.3%
Regions Covered
Global
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Market Overview
Biology of Prostate Cancer
Symptoms
Screening
Diagnosis
Metastatic Prostate Cancer
Watchful Waiting or Active Surveillance
Treatment
Chapter 4 Market Dynamics
Market Drivers
Increasing Prevalence of Prostate Cancer
Active Surveillance and Screening
Approvals for Metastatic Castration-Resistant Prostate Cancer
Collaborations and Licensing Agreements
Market Challenges
Loss of Exclusivity and Genericization
Shortage of Care Providers and Other Resources
Market Opportunities
Chapter 5 Screening and Diagnosis Market by Test Type
Biomarker Tests
PSA Tests
Limitations of PSA Tests
Biomarker Tests for Early Prostate Cancer Detection in Elevated PSA Settings
Digital Rectal Exam
Limitations of DREs
Prostate Biopsy
Grade (Gleason Score) of Prostate Cancer
Atypical Small Acinar Proliferation
Proliferative Inflammatory Atrophy
Limitations of Prostate Biopsies
Market for Prostate Cancer Screening/Diagnosis, by Test Type
Biomarker Tests
DREs
Prostate Biopsies
Chapter 6 Pharmaceuticals Market by Drug Type
Hormone Therapy
Androgen Deprivation Therapy
Antiandrogen Therapies
Hormone Therapy Uses in Prostate Cancer Treatment
Targeted Therapy
PARP InhibitorsPARP Inhibitors
Radioligand Therapies
Small Molecule Targeted Agents
Monoclonal Antibodies
Chemotherapy
Immunotherapy
Market Revenue, by Drug Type
Hormone Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
Chapter 7 Market for Surgery and Radiation Therapy by Treatment Type
Active Surveillance
Radical Prostatectomy
Robotic Prostatectomy
Open Radical Prostatectomy
Laparoscopic Prostatectomy
Radical Prostatectomy Market Revenue
Radiation Therapy
External Beam Radiation Therapy
Brachytherapy
Combined Radiation Therapy
Radiation Therapy Device Market Revenue
Chapter 8 Market Breakdown by Region
Chapter 9 Emerging Technologies and Developments
Liquid Biopsy
Multiparametric MRI
Homologous Recombination Repair Gene Mutation
Advanced Radiotherapy Techniques
AI and Machine Learning
Chapter 10 Pipeline Analysis
Chapter 11 Competitive Intelligence
Screening and Diagnosis Market
Market for Radiation Therapy Devices
Pharmaceuticals Market
Chapter 12 Company Profiles
Abbott
Accuray
Bayer
Elekta
Siemens Healthineers
For more information about this report visit https://www.researchandmarkets.com/r/wra8q3
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。